Evaluation of the effectiveness of a broad-spectrum sunscreen in the prevention of chloasma in pregnant women

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 6, 2007, Pages 738-742

  Lakhdar, Hakima ^a   Zouhair, K ^a   Khadir, K ^a   Essari, A ^a   Richard, A ^b   Seite S ^b   Rougier, A ^b  

^a IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

^b La Roche Posay Pharmaceutical Laboratories   (France)

Author keywords

Broad spectrum sunscreen; Chloasma; Melasma; Pregnancy; UVB UVAprotection

Indexed keywords

ANTHELIOS XL; SUNSCREEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHLOASMA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLORIMETRY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL CARE; OUTCOME ASSESSMENT; PREGNANCY COMPLICATION; PREGNANT WOMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SKIN CARE; SKIN COLOR; SKIN PIGMENTATION; SKIN PROTECTION; TREATMENT DURATION; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; FEMALE; HUMANS; MELANOSIS; PREGNANCY; PREGNANT WOMEN; STATISTICS, NONPARAMETRIC; SUNSCREENING AGENTS; TREATMENT OUTCOME;

EID: 34250679354     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02185.x     Document Type: Article

References (18)

1. Cayce KA, McMichael AJ, Felman SR. Hyperpigmentation: An overview of the common afflictions. Dermatol Nurs 2004; 16: 413-416.
2. Balkrishnan R, Kelly AP, McMichael A, Torok H. Improved quality of life with effective treatment of facial melasma: The pigment trial. J Drugs Dermatol 2004; 3: 377-381.
3. Perez ML. The stepwise approach to the treatment of melasma. Cutis 2005; 75: 217-222.
4. Victor FC, Gelber J, Rao B. Melasma: A review. J Cutan Med Surg 2004; 8: 97-102.
5. Muzaffar F, Hussain J, Haroo HS. Physiologic skin changes during pregnancy: A study of 140 cases. Int J Dermatol 1998; 37: 429-431.
6. Errickson C, Matus NR. Skin disorders of pregnancy. Am Fam Physician 1994; 49: 605-610.
7. Jimbow K, Minamitsuji Y. Topical therapies for melasma and disorders of hyperpigmentation. Dermatol Ther 2001; 14: 35-45.
8. Sharquie KE, Al-Tirkreety MM, Al-Mahhadani SA. Lactic acid as a new therapeutic peeling agent in melasma. Dermatol Surg 2005; 31: 149-154.
9. Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol 2004; 43: 604-607.
10. Torok HM, Jones T, Rich P, Smith S, Tschen E. Hydroquinone 4%, tretinoin 0.05%, flucinolone acetonide 0.01%: A safe and efficious 12-month treatment for melasma. Cutis 2005; 75: 57-62.
11. Benchikhi H, Razoli H, Lakhdar H. Sunscreens: Use in pregnant women in Casablanca. Ann Dermatol Venereol 2002; 129: 387-390.
12. The European Cosmetic Toiletry and Perfumery Association. SPF Test Method. COLIPA, Brussels, Belgium, May, 1994.
13. Japan Cosmetic industry association. Measurements Standard for UVA Protection Efficacy. JCIA, Tokyo, Japan, 1996.
14. Wendel V, Klette E, Gers-Barlag H. A new in vitro test method to assess the UVA protection performance of sun care products. SÖFW-J 2001; 12-16: 29-30.
15. Takiwaki A. Measurement of skin color: Practical application and theoretical considerations. J Med Invest 1998; 44: 121-126.
16. Barankin B, Silver SG, Carruthers A. The skin in pregnancy. J Cutan Med Surg 2002; 6: 236-240.
17. Alves GF, Nogueira LSC, Varella TCN. Dermatology and pregnancy. An Bras Dermatol 2005; 80: 179-186.
18. Khadir K, Amal S, Hali F, Nejjam F, Lakhdar H. Les signes dermatologiques physiologiques de la grossesse. Ann Dermatol Venereol 1999; 126: 15-19.